1982-87, Jinzhou Medical College, Jinzhou, P.R.C., M.D. , Medicine
1988-94, Medical College of Ohio, Toledo, Ohio, Ph.D., Pathology
1997-2002, UCSF, Staff Research Associate, Dept. of Surgery, UCSF Comprehensive Cancer Center
Thoracic Oncology Program
Thoracic Oncology Laboratory
UCSF Helen Diller Family Comprehensive Cancer Center
Akt Signaling Pathway
Human cancer genetics and epigenetics
Lung cancer and mesothelioma
Molecular analysis on matched normal/tumor tissues
Small molecules, antibodies and recombinant proteins
Wnt Signaling Pathway
Dr. Liang You received his M.D. in 1987 from the Jinzhou Medical College in China and his Ph.D. in pathology from the Medical College of Ohio in 1994. He began work at UCSF in the thoracic oncology laboratory after work at the National Cancer Institute. At UCSF, Dr. You has made a significant impact on lung cancer and mesothelioma research. Most notably, he has been been instrumental in helping Dr. David Jablons mold a fledgling research effort into a thriving molecular genomics laboratory, an integral part of the Comprehensive Cancer Center and nationally recognized.
In November 2007, Dr. You was presented with the David Jablons "Asclepios" Award by the Bonnie J. Addario Lung Cancer Foundation for his pioneering research.
Dr. You has been a creative and dynamic force in the lab and his work has led to numerous discoveries. He helped demonstrate the relationship of p14ARF tumor suppressor deletions to the p53 pathway in mesothelioma and the effects of oncolytic viruses upon these tumors. He also discovered several novel mechanisms for the activation of upstream WNT pathways.
Dr. You has helped identify several novel biomarkers and therapeutic targets in lung cancer and mesothelioma. He and his colleagues demonstrated overexpression of Dishevelled-3 and silencing of SFRP-2, SOCS-3 and WIF-1 through promoter methylation. Dr. You and chemist Dr. Naoaki Fujii developed a small molecule Wnt pathway inhibitor, FJ9, that disrupts the interaction between the Frizzled receptor and Dishevelled, a Wnt signal transducer.
Dr. You is currently investigating the use of recombinant human WIF-1 protein as a cancer therapy and seeking out new therapeutic targets and novel interventions.
Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2a, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014; 33(1):93. View in PubMed
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996. View in PubMed
Uematsu K, Seki N, Seto T, Isoe C, Tsukamoto H, Mikami I, You L, He B, Xu Z, Jablons DM, Eguchi K. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res. 2007 Nov-Dec; 27(6B):4239-42. View in PubMed
Reguart N, He B, Taron M, You L, Jablons DM, Rosell R. The role of Wnt signaling in cancer and stem cells. Future Oncol. 2005 Dec; 1(6):787-97. View in PubMed
Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg. 2004 Aug; 78(2):436-43; discussion 436-43. View in PubMed
Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. 2003 Jan-Feb; 23(1A):33-8. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.